← All trials
NCT06453317
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2024
- Primary completion
- Apr 30, 2028
- Completion date
- Jun 30, 2028
- First posted
- Jun 11, 2024
- Last posted
- Jun 11, 2024
- Enrollment
- 172
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medical University of LodzLead sponsor
- Poznan UniversityCollaborator
- Medical University of LodzSponsor investigator
- Medical University of LodzOfficial
- K. Marcinkowski University of Medical SciencesCollaborator
- Government of PolandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.